Trade Jazz Pharmaceuticals plc - JAZZ CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.40 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 124.02 |
| Open | 122.42 |
| 1-Year Change | 1.83% |
| Day's Range | 122.42 - 127.13 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 124.02 | 3.01 | 2.49% | 121.01 | 124.51 | 119.83 |
| Mar 28, 2025 | 122.38 | -2.74 | -2.19% | 125.12 | 125.78 | 122.31 |
| Mar 27, 2025 | 125.82 | -4.13 | -3.18% | 129.95 | 130.20 | 125.77 |
| Mar 26, 2025 | 130.75 | -3.26 | -2.43% | 134.01 | 134.55 | 127.51 |
| Mar 25, 2025 | 134.78 | -6.00 | -4.26% | 140.78 | 141.79 | 133.65 |
| Mar 24, 2025 | 141.49 | 2.90 | 2.09% | 138.59 | 142.46 | 138.59 |
| Mar 21, 2025 | 138.75 | 0.65 | 0.47% | 138.10 | 139.81 | 136.07 |
| Mar 20, 2025 | 139.90 | 0.12 | 0.09% | 139.78 | 141.37 | 138.70 |
| Mar 19, 2025 | 141.46 | 2.06 | 1.48% | 139.40 | 142.15 | 139.40 |
| Mar 18, 2025 | 139.41 | 1.36 | 0.99% | 138.05 | 140.48 | 137.79 |
| Mar 17, 2025 | 140.11 | 2.93 | 2.14% | 137.18 | 140.77 | 136.64 |
| Mar 14, 2025 | 137.50 | 1.60 | 1.18% | 135.90 | 138.00 | 134.47 |
| Mar 13, 2025 | 135.50 | 2.18 | 1.64% | 133.32 | 137.82 | 133.22 |
| Mar 12, 2025 | 133.71 | -2.17 | -1.60% | 135.88 | 136.37 | 133.61 |
| Mar 11, 2025 | 136.22 | 0.60 | 0.44% | 135.62 | 138.30 | 133.91 |
| Mar 10, 2025 | 136.95 | 0.27 | 0.20% | 136.68 | 139.82 | 136.39 |
| Mar 7, 2025 | 138.17 | 0.16 | 0.12% | 138.01 | 140.88 | 137.17 |
| Mar 6, 2025 | 136.20 | -2.28 | -1.65% | 138.48 | 139.60 | 135.31 |
| Mar 5, 2025 | 140.11 | 2.40 | 1.74% | 137.71 | 142.70 | 137.05 |
| Mar 4, 2025 | 140.14 | 2.51 | 1.82% | 137.63 | 140.74 | 137.63 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Jazz Pharma Company profile
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Jazz Pharmaceuticals PLC revenues increased 31% to $3.09B. Net loss totaled $329.7M vs. income of $238.6M. Revenues reflect Sunosi segment increase from $28.3M to $2.34B, Zepzelca segment increase from $90.4M to $246.8M, United States segment increase of 32% to $2.82B, Europe segment increase of 31% to $230.2M. Net loss reflects Selling.
Equity composition
Common Stock $.0001 Par, 4/11, 150M auth., 40,741,809 issd. Insiders & stakeholders own 2.30%. IPO 6/1/07, 6M shares @ $18 per share by Morgan Stanley & Co. Incorporated, Lehman Brothers Inc. 5/07 Reverse stock split 1 for 11.06701. PO: 7/08, 3.8M shares.
| Industry: | Pharmaceuticals (NEC) |
Fifth Fl
Waterloo Exchange
DUBLIN
DUBLIN 4
IE
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com